Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers

Wspolczesna Onkologia

Volumn 19, Issue 2, 2015, Pages 157-162

  Kast, Richard E ^a  

^a IIAIGC Study Center   (United States)

Author keywords

Agomelatine; Cusp9 ^{< sup>; Glioblastoma; Interleukin 2; Melatonin; Ramelteon; Temozolamide}

Indexed keywords

AGOMELATINE; INTERLEUKIN 2; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; RAMELTEON;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG ABSORPTION; DRUG HALF LIFE; GLIOBLASTOMA; HUMAN; POLYPHARMACY; TUMOR GROWTH;

EID: 84929399502     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2015.51421     Document Type: Article

References (65)

1. Kast RE, Karpel-Massler G, Halatsch ME. CUSP9∗ treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget 2014;5:8052-82.
2. Kast RE, Boockvar JA, Bruning A, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget 2013;4:502-30.
3. Xie Q, Mittal S, Berens ME. Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro Oncol 2014; pii: nou147.
4. Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res 2012;52:365-75.
5. Barrenetxe J, Delagrange P, Martinez JA. Physiological and metabolic functions of melatonin. J Physiol Biochem 2004;60:61-72.
6. Reiter RJ, Tan DX, Galano A. Melatonin: Exceeding Expectations. Physiology (Bethesda) 2014;29:325-33.
7. Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today 2014;19:1410-8.
8. Hardeland R. Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. ScientificWorldJournal 2012;2012:640389.
9. Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem 2014;57:3161-85.
10. Campbell BM, Charych E, Lee AW, Möller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci 2014;8:12.
11. Oxenkrug G. Serotonin-kynurenine hypothesis of depression: historical overview and recent developments. Curr Drug Targets 2013;14:514-21.
12. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr. The absolute bioavailability of oral melatonin. J Clin Pharmacol 2000;40:781-4.
13. Hardeland, R. New approaches in the management of insomnia: weighing the advantages of prolonged release melatonin and synthetic melatoninergic agonists. Neuropsychiatr. Dis Treat 2009;5:341-54.
14. Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP. Melatonergic drugs in clinical practice. Arzneimittelforschung 2008;58:1-10.
15. Acuna-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 2014;71:2997-3025.
16. Itoh MT, Shinozawa T, Sumi Y. Circadian rhythms of melatonin-synthesizing enzyme activities and melatonin levels in planarians. Brain Res 1999;830:165-73.
17. Tosches MA, Bucher D, Vopalensky P, Arendt D. Melatonin signaling controls circadian swimming behavior in marine zooplankton. Cell 2014;159:46-57.
18. Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, Garcia-Maurino S, Reiter RJ, Guerrero JM. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004;18:537-9.
19. Carrillo-Vico A, Lardone PJ, Fernandez-Santos JM, Martin-Lacave I, Calvo JR, Karasek M, Guerrero JM. Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin-2/interleukin-2 receptor system. J Clin Endocrinol Metab 2005;90:992-1000.
20. Lardone PJ, Guerrero JM, Fernandez-Santos JM, Rubio A, Martin-Lacave I, Carrillo-Vico A. Melatonin synthesized by T lymphocytes as a ligand of the retinoic acid-related orphan receptor. J Pineal Res 2011;51:454-62.
21. Calvo JR, Gonzalez-Yanes C, Maldonado MD. The role of melatonin in the cells of the innate immunity: a review. J Pineal Res 2013;55:103-20.
22. Chen Q, Wei W. Effects and mechanisms of melatonin on inflammatory and immune responses of adjuvant arthritis rat. Int Immunopharmacol 2002;2:1443-9.
23. Tan DX, Manchester LC, Sanchez-Barcelo E, Mediavilla MD, Reiter RJ. Significance of high levels of endogenous melatonin in Mammalian cerebrospinal fluid and in the central nervous system. Curr Neuropharmacol 2010;8:162-7.
24. Chen CQ, Fichna J, Bashashati M, Li YY, Storr M. Distribution, function and physiological role of melatonin in the lower gut. World J Gastroenterol 2011;17:3888-98.
25. Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP, Cardinali DP. Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov 2011;5:109-23.
26. Cutando A, Lopez-Valverde A, Arias-Santiago S, DE Vicente J, DE Diego RG. Role of melatonin in cancer treatment. Anticancer Res 2012;32:2747-53.
27. Bizzarri M, Proietti S, Cucina A, Reiter RJ. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets 2013;17:1483-96.
28. Rondanelli M, Faliva MA, Perna S, Antoniello N. Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks. Aging Clin Exp Res 2013;25:499-510.
29. Zarogoulidis P, Darwiche K, Huang H, Spyratos D, Yarmus L, Li Q, Kakolyris S, Syrigos K, Zarogoulidis K. Time recall; future concept of chronomodulating chemotherapy for cancer. Curr Pharm Biotechnol 2013;14:632-42.
30. Antoniou A, Hebrant A, Dom G, Dumont JE, Maenhaut C. Cancer stem cells, a fuzzy evolving concept: a cell population or a cell property? Cell Cycle 2013;12:3743-8.
31. Bayin NS, Modrek AS, Placantonakis DG. Glioblastoma stem cells: Molecular characteristics and therapeutic implications. World J Stem Cells 2014;6:230-8.
32. Kast RE, Belda-Iniesta C. Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis. Curr Stem Cell Res Ther 2009;4:314-7.
33. Binda E, Reynolds BA, Vescovi AL. Glioma stem cells: turpis omen in nomen? (The evil in the name?). J Intern Med 2014;276:25-40.
34. Martin V, Sanchez-Sanchez A, Puente-Moncada N, Gomez-Lobo M, Alvarez-Vega MA, Antolin I, Rodriguez C. Involvement of autophagy in melatonin-induced cytotoxicity in glioma-initiating cells. J Pineal Res 2014;57:308-16.
35. Martin V, Sanchez-Sanchez AM, Herrera F, Gomez-Manzano C, Fueyo J, Alvarez-Vega MA, Antolin I, Rodriguez C. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer 2013;108:2005-12.
36. Wilson TA, Karajannis MA, Harter DH. Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int 2014;5:64.
37. Zhang Y, Liu Q, Wang F, et al. Melatonin antagonizes hypoxia-mediated glioblastoma cell migration and invasion via inhibition of HIF-1α. J Pineal Res 2013;55:121-30.
38. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, Maestroni G. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 1996;53:43-6.
39. Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Nat Immun 1998;16:27-33.
40. Owen RT. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today (Barc) 2009;45:599-608.
41. Pompili M, Serafini G, Innamorati M, Venturini P, Fusar-Poli P, Sher L, Amore M, Girardi P. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. World J Biol Psychiatry 2013;14:412-31.
42. Cavallo A, Ritschel WA. Pharmacokinetics of melatonin in human sexual maturation. J Clin Endocrinol Metab 1996;81:1882-6.
43. Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013;203:179-87.
44. Smeraldi E, Delmonte D. Agomelatine in depression. Expert Opin Drug Saf 2013;12:873-80.
45. Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 2010;25:305-14.
46. Plesničar BK. Efficacy and tolerability of agomelatine in the treatment of depression. Patient Prefer Adherence 2014;8:603-12.
47. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014;348:g1888.
48. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007;10:661-73.
49. Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP. Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther 2009;26:613-26.
50. McGechan A, Wellington K. Ramelteon. CNS Drugs 2005;19:1057-65.
51. Simpson D, Curran MP. Ramelteon: a review of its use in insomnia. Drugs 2008;68:1901-19.
52. Greenblatt DJ, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol 2007;47:485-96.
53. Kast RE, Altschuler EL. Co-administration of ramelteon and fluvoxamine to increase levels of interleukin-2. Med Hypotheses 2006;67:1389-90.
54. Obach RS, Ryder TF. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos 2010;38:1381-91.
55. FDA labelling information [online]. http://www.fda.gov/cder/foi/label/2005/021782lbl.pdf; 2005.
56. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014;192:5451-8.
57. Waldmann T, Tagaya Y, Bamford R. Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol 1998;16:205-26.
58. McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, Thompson JA, Balch CM. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 2014;40:1056-1064.
59. Rosalia RA, Arenas-Ramirez N, Bouchaud G, Raeber ME, Boyman O. Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Curr Opin Chem Biol 2014;23C:39-46.
60. Sanchez-Hidalgo M, Lee M, de la Lastra CA, Guerrero JM, Packham G. Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines. J Pineal Res 2012;53:366-73.
61. Ha E, Han E, Park HJ, et al. Microarray analysis of transcription factor gene expression in melatonin-treated human peripheral blood mononuclear cells. J Pineal Res 2006;40:305-11.
62. Garcia-Maurino S, Pozo D, Calvo JR, Guerrero JM. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. J Pineal Res 2000;29:129-37.
63. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafii-El-Idrissi M, Sanchez-Margalet V, Goberna R, Guerrero JM. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol 1997;159:574-81.
64. Yan JJ, Shen F, Wang K, Wu MC. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study. Hepatobiliary Pancreat Dis Int 2002;1:183-6.
65. An Y, Liu E, Liu X, Yang F, Han F, Dai Q. Protective effect of melatonin on neural cells against the cytotoxicity of oxyradicals. Chin Med Sci J 2000;15:40-4.